Chugai: Lilly’s Foundayo (orforglipron) FDA-approved for weight loss
Key highlights
- FDA approved orforglipron (Foundayo) for adults with obesity or overweight with weight-related medical conditions on April 1, 2026.
- The drug is an oral GLP-1 therapy intended to be used with a reduced-calorie diet and increased physical activity for weight loss and maintenance.
- Foundayo was discovered by Chugai and is exclusively licensed to Eli Lilly for global development and commercialization.
FDA approval
On April 1, 2026 (U.S. local time), the U.S. Food and Drug Administration approved orforglipron (Foundayo) for adults with obesity or overweight who have weight-related medical conditions.
Indication and use
The approval specifies that Foundayo is to be used alongside a reduced-calorie diet and increased physical activity to support weight loss and maintenance.
Origin and licensing
Foundayo was discovered by Chugai Pharmaceutical and is exclusively licensed to Eli Lilly and Company for global development and commercialization; Chugai issued its announcement on April 2, 2026.
Source: Chugai Pharmaceutical